The polyomavirus family currently includes thirteen human polyomavirus (HPyV) 11 species. In immunocompromised and elderly persons HPyVs are known to cause disease, 12 such as progressive multifocal leukoencephalopathy (JCPyV), haemorrhagic cystitis and 13 nephropathy (BKPyV), Merkel cell carcinoma (MCPyV), and trichodysplasia spinulosa 14 (TSPyV). Some recently discovered polyomaviruses are of still unknown prevalence and 15 pathogenic potential. Because HPyVs infections persist and might be transferred by blood 16 components to immunocompromised patients, we studied the seroprevalence of fourteen 17 polyomaviruses in adult Dutch blood donors. For most polyomaviruses the observed 18 seroprevalence was high (60-100%), sometimes slightly increasing or decreasing with age. 19 Seroreactivity increased with age for JCPyV, HPyV6 and HPyV7 and decreased for BKPyV 20 and TSPyV. The most recently identified polyomaviruses HPyV12, NJPyV and LIPyV 21 showed low overall seroprevalence (5%) and low seroreactivity, questioning their human 22 tropism. Altogether, HPyV infections are common in Dutch blood donors, with an average of 23 nine polyomaviruses per subject. 24 25 polyomavirus called the Lyon IARC polyomavirus (LIPyV) that was identified in 2017 has 33 not been assigned to a polyomavirus species yet [4]. 34 BKPyV is the main cause of polyomavirus-associated nephropathy (PVAN) that 35 occurs in up to 10% of kidney transplant patients [5]. Haemorrhagic cystitis, also caused by 36 BKPyV, complicates between 6-30% of hematopoietic stem cell transplantations [6]. JCPyV 37 causes progressive multifocal leukoencephalopathy (PML), a potentially lethal, 38 demyelinating brain disease, which is found in HIV-infected AIDS patients, 39 immunosuppressed transplantation patients, and nowadays especially in multiple sclerosis 40 (MS) patients treated with immunomodulatory drugs, such as natalizumab [7]. The incidence 41 of PML in natalizumab-treated MS patients can be as high as 20 per 1000 patients [8,9]. 42 Merkel cell polyomavirus (MCPyV) is an important cause of Merkel cell carcinoma (MCC). 43 The incidence of MCC is low, approximately 0.4 per 100.000 person-years, though this 44 appears to increase [10]. Less is known about the incidence of diseases caused by other 45 polyomaviruses, for example trichodysplasia spinulosa caused by the trichodysplasia 46 spinulosa polyomavirus (TSPyV) [2,11]. Karolinska Institute polyomavirus (KIPyV) and 47 seroreactivity were determined of fourteen polyomaviruses identified thus far in humans, in 58 1050 Dutch blood donors subdivided into age categories. HPyV serology was performed 59 using a custom bead-based immunoassay which was recently validated for this purpose [19]. 60 61 Materials and methods 62 Study population 63
Introduction 26
The Polyomaviridae family comprises non-enveloped double-stranded DNA viruses 27 that infect a broad spectrum of hosts. After primary infection, usually in childhood, they Blood components (red blood cells, platelets and fresh frozen plasma) are 53 administered to haematological, transplant, and other immunocompromised patients in huge 54 numbers. Therefore, it is important to understand the epidemiology of polyomaviruses among 55 healthy adults and potential blood donors, including HPyVs that have been recognized just 56 recently and of which still very little is known. In this study the seroprevalence and 57 Human polyomavirus multiplex immunoassay 79 A customized, recently described Luminex xMAP assay was used to measure IgG 80 seroreactivity against the VP1 major capsid protein of BKPyV, JCPyV, KIPyV, WUPyV, beads coupled to an irrelevant GST fusion protein, in this case GST-SV40 small T-antigen.
97
Serum samples with a high response against GST-SV40 small T-antigen (resulting in specific 98 seroreactivity below or equal to minus 1000 MFI), were excluded for further analysis (n=6). Table 2 ). However, for HPyV9 and especially for HPyV12, 125 NJPyV and LIPyV the overall seropositivity was low, 19.2%, 4.0%, 5.2% and 5.9% Human polyomavirus seroreactivity 140 Seroreactivity detected in seropositive donors differed between the analysed HPyVs.
99

Determination of the cut-off value
141
The highest median MFI-values were measured for BKPyV (Fig 4) In general, no differences in seroreactivity between the sexes were observed, but for 155 HPyV7 the overall median seroreactivity among seropositives was higher in men (9250 MFI 156 in men vs. 6464 MFI in women, P=0.018). studies are needed to solve these discrepancies and to define the natural host(s) of these 220 viruses, for example by studying seroprevalence in different geographic regions while using 221 comparable serological methods.
222
In conclusion, by analysing a large group of Dutch blood donors we showed that most 
